Drugs / FZ-AD005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07455045 | Mar 2026 → Dec 2027 expected | glioblastoma | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06424665 | Jul 2024 → Aug 2026 overdue | neoplasm | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-02 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Results 抗DLL3抗体偶联BB05项目用于治疗晚期实体瘤之临床前研究论文发布 fd-zj.com ↗
本公司在临床前研究的评估中，该药物展现出与DLL3靶点特异性结合，并在人源肿瘤细胞系异种移植模型（CDX）和患者来源异种移植模型（PDX）中表现出高效的内化、旁观者杀伤和出色的体内抗肿瘤活性。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-07-02 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | 抗DLL3抗体偶联BB05项目用于治疗晚期实体瘤之临床前研究论文发布 fd-zj.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FZ-AD005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07455045 ↗ |
| Modality | Other / unclassified | “FZ-AD005 Antibody-Drug Conjugate” NCT07455045 ↗ |
| Route | Intravenous | “Subjects will receive an intravenous infusion of FZ-AD005” NCT06424665 ↗ |